Allison Nguyen

Researchers compared the efficacy between ustekinumab and vedolizumab for treating extraintestinal manifestations of inflammatory bowel disease.

Researchers tested the effectiveness of pharmacist de-prescribing strategies for decreasing inappropriate ICU-initiated acid suppression therapy.